Rising asthma prevalence and increasing environmental pollution to drive the Global Asthma Therapeutics Market

According to a recently published report by Brisk Insights, the Global Asthma Therapeutics Market is expected to grow at the CAGR of 2.5 % during 2017-2025. The global asthma therapeutics market is segmented on the basis of drug class, product, route of administration and geography. The report on global asthma therapeutics market (by drug class, product, route of administration and geography) provides a detailed overview and predictive analysis of the market.

Full report available on Asthma Therapeutics Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/asthma-therapeutics-market

Market Insights

Rising asthma prevalence and increasing environmental pollution are the key growth factors in the asthma therapeutics market. In base year 2016, combination therapy accounted for the largest market share the drug class segment as the first line of treatment for asthma treatment is inhaled corticosteroids (ICS) with long-acting beta agonists (LABA). The driving factors of this market are rising prevalence of asthma and growing patient compliance. Metered dose inhalers held the largest market in the product segments due to factors such as immediate relief from asthma attack, controlled dose and direct release of drugs in the respiratory system. Inhalation dominates the route of administration segment chiefly due to factors such as rapid onset of action, less systemic toxicity and higher concentration availability at the site of action.

The asthma therapeutics market is currently dominated by North America due to increasing number of patients suffering with asthma, rising public awareness regarding asthma and early treatment, and supportive reimbursement policies. On the other hand, Asia Pacific is anticipated to be the fastest growing market because of deep market penetration due to increasing prevalence of asthma rapid industrialization causing increased air pollution, growing disposable income and developing healthcare infrastructure.

Scope of the report

1. Global Asthma Therapeutics market, by Drug Class, 2015–2025 ($ Million)

1.1. Anti-inflammatory drugs
1.2. Bronchodilators
1.3. Combination therapy

2. Global Asthma Therapeutics market, by Product, 2015–2025 ($ Million)

2.1. Dry Powder Inhalers (DPI)
2.2. Metered Dose Inhalers (MDI)
2.3. Mist Inhaler
2.4. Nebulizer

3. Global Asthma Therapeutics market, by Route of Administration, 2015–2025 ($ Million)

3.1. Inhalation
3.2. Oral
3.3. Parenteral

4. Global Asthma Therapeutics market, by Geography, 2015-2025 ($ Million)

4.1. North America
4.1.1. U.S.
4.1.2. Canada
4.2. Europe
4.2.1. U.K.
4.2.2. Germany
4.2.3. Rest of Europe
4.3. Asia Pacific
4.3.1. Japan
4.3.2. China
4.3.3. Rest of Asia Pacific
4.4. Latin America
4.4.1. Mexico
4.4.2. Brazil
4.4.3. Rest of Latin America
4.5. Middle East and Africa
4.5.1. GCC
4.5.2. Rest of Middle East and Africa

5. Company Profiles

5.1. Abbott Laboratories
5.2. AstraZeneca
5.3. Becton, Dickinson and Company
5.4. Boehringer Ingelheim GmbH
5.5. Chiesi Farmaceutici
5.6. F. Hoffmann-La Roche
5.7. GlaxoSmithKline Plc.
5.8. Merck& Co., Inc.
5.9. Pfizer
5.10. Philips Healthcare
5.11. Sanofi-Aventis SA
5.12. Sunovion Pharmaceuticals, Inc.
5.13. Teva Pharmaceutical Industries Ltd.
5.14. Others